Fermentation process for the production of pyrimidine deoxyribonucleosides
CA 2070826 C · Owner: Glaxo Group Limited · Inventors: Anderson, David M.; Mccandliss, Russell J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
DNA coding for at least one enzyme that causes the accumulation of a pyrimidine deoxyribonucleoside is used in con-, junction with metabolic mutations or heterologous DNA coding for metabolic enzymes that also increase pyrimidine deoxyribonucleoside production, to engineer cultured cells to express a pyrimidine deoxyribonucleoside (PdN) in recoverable quantities pro-, viding a commercially useful fermentation source for PdNs.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 5, 1990 and granted October 30, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 5, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 5, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.